Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: A retrospective investigation
- 15 October 2017
- journal article
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 30 (6), e12559
- https://doi.org/10.1111/dth.12559
Abstract
Pityriasis rubra pilaris (PRP) is a rare, difficult to treat papulosquamous disorder that responds variably to retinoids and immunosuppression. Successful use of biologics for treating PRP has been described in the literature by case reports and a limited number of case series. To provide additional data, we retrospectively analyzed cases of PRP treated with biologics at our institution. We identified seven patients with a clear diagnosis of PRP treated with adalimumab, etanercept, and/or ustekinumab at our institution from January 1, 2014 to April 1, 2017. Six of seven patients had type I, adult acquired PRP, and one had type V atypical juvenile PRP. In response to tumor necrosis factor (TNF)-α inhibition, two patients had marked responses (>75% improvement in involved body surface area), while three patients failed to show any improvement on a TNF-α inhibitor. In two cases of PRP refractory to TNF-α inhibition, ustekinumab resulted in a partial response (<75% improvement) in one patient and no response in the other. Compared to other published data, our cohort was substantially more resistant to treatment with biologics, a finding which may provide valuable perspective for dermatologists managing refractory PRP in the future.Keywords
This publication has 11 references indexed in Scilit:
- Epidemiologic, Clinicopathologic, Diagnostic, and Management Challenges of Pityriasis Rubra PilarisJAMA Dermatology, 2016
- Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor ApremilastJAMA Dermatology, 2016
- Ustekinumab as an Alternative Treatment Option for Chronic Pityriasis Rubra PilarisCase Reports in Dermatology, 2015
- Pityriasis Rubra Pilaris : Failure of Treatment with InfliximabThe Nishinihon Journal of Dermatology, 2014
- Treatment Options for Pityriasis Rubra Pilaris Including Biologic AgentsJAMA Dermatology, 2014
- Pityriasis rubra pilaris types 1 and 2: different responses to treatment with TNF-alpha antagonistsEuropean Journal of Dermatology, 2013
- A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonistsJournal of the European Academy of Dermatology and Venereology, 2012
- Treatment of refractory adult‐onset pityriasis rubra pilaris with TNF‐alpha antagonists: a case seriesJournal of the European Academy of Dermatology and Venereology, 2010
- Pityriasis Rubra PilarisAmerican Journal of Clinical Dermatology, 2010
- Pityriasis rubra pilaris*Clinical and Experimental Dermatology, 1980